ATREZLYON Trademark
Trademark Overview
On Wednesday, December 17, 2025, a trademark application was filed for ATREZLYON with the United States Patent and Trademark Office. The USPTO has given the ATREZLYON trademark a serial number of 99552327. The federal status of this trademark filing is PUBLISHED FOR OPPOSITION as of Tuesday, May 26, 2026. This trademark is owned by Juno Therapeutics, Inc.. The ATREZLYON trademark is filed in the Pharmaceutical Products category with the following description:
Pharmaceutical preparations for the treatment and prevention of obesity, cardiovascular diseases, central nervous system diseases, metabolic disorders, stroke, cancer, inflammatory diseases, respiratory diseases, infectious diseases, auto-immune diseases, solid organ transplant rejection, autoinflammatory disease, blood disease, multiple sclerosis, ulcerative colitis, cystic fibrosis, arthritis, and musculoskeletal and skin disease; Antivirals; Antibodies for medical purposes; Biological preparations for the treatment of cancer; Anticoagulants; Stem cells for medical purposes; Radiopharmaceutical preparations for the treatment of cancer and solid tumors; Diagnostic radiopharmaceutical preparations; Diagnostic preparations for medical purposes
General Information
| Serial Number | 99552327 |
| Word Mark | ATREZLYON |
| Filing Date | Wednesday, December 17, 2025 |
| Status | 686 - PUBLISHED FOR OPPOSITION |
| Status Date | Tuesday, May 26, 2026 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, May 26, 2026 |
Trademark Statements
| Goods and Services | Pharmaceutical preparations for the treatment and prevention of obesity, cardiovascular diseases, central nervous system diseases, metabolic disorders, stroke, cancer, inflammatory diseases, respiratory diseases, infectious diseases, auto-immune diseases, solid organ transplant rejection, autoinflammatory disease, blood disease, multiple sclerosis, ulcerative colitis, cystic fibrosis, arthritis, and musculoskeletal and skin disease; Antivirals; Antibodies for medical purposes; Biological preparations for the treatment of cancer; Anticoagulants; Stem cells for medical purposes; Radiopharmaceutical preparations for the treatment of cancer and solid tumors; Diagnostic radiopharmaceutical preparations; Diagnostic preparations for medical purposes |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, December 17, 2025 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | Juno Therapeutics, Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Seattle, WA 98109
US |
| Party Name | Juno Therapeutics, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Seattle, WA 98109
US |
Trademark Events
| Event Date | Event Description |
| Wednesday, December 17, 2025 | NEW APPLICATION ENTERED |
| Wednesday, December 17, 2025 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Wednesday, December 17, 2025 | APPLICATION FILING RECEIPT MAILED |
| Monday, April 20, 2026 | ASSIGNED TO EXAMINER |
| Saturday, April 25, 2026 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, May 20, 2026 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, May 26, 2026 | PUBLISHED FOR OPPOSITION |
| Tuesday, May 26, 2026 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
